Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arvinas, Inc. stock logo
ARVN
Arvinas
$9.61
-0.6%
$11.29
$5.90
$14.51
$622.81M1.79844,391 shs727,839 shs
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
$14.00
-1.0%
$14.84
$12.15
$67.01
$165.39MN/A4,514 shs126 shs
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$3.86
-0.1%
$4.59
$1.72
$8.21
$652.68M2.185.69 million shs341,251 shs
Enhabit, Inc. stock logo
EHAB
Enhabit
$13.80
+0.1%
$13.75
$6.47
$14.22
$706.66M1.261.18 million shs214,619 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arvinas, Inc. stock logo
ARVN
Arvinas
-4.45%-8.09%-10.72%-28.13%+46.14%
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
-1.74%-4.13%-7.47%+1,414,999,900.00%+1,414,999,900.00%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-3.02%-7.66%-12.07%-30.20%+315.77%
Enhabit, Inc. stock logo
EHAB
Enhabit
+0.07%+0.36%-1.35%+23.17%+34.59%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arvinas, Inc. stock logo
ARVN
Arvinas
$9.61
-0.6%
$11.29
$5.90
$14.51
$622.81M1.79844,391 shs727,839 shs
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
$14.00
-1.0%
$14.84
$12.15
$67.01
$165.39MN/A4,514 shs126 shs
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$3.86
-0.1%
$4.59
$1.72
$8.21
$652.68M2.185.69 million shs341,251 shs
Enhabit, Inc. stock logo
EHAB
Enhabit
$13.80
+0.1%
$13.75
$6.47
$14.22
$706.66M1.261.18 million shs214,619 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arvinas, Inc. stock logo
ARVN
Arvinas
-4.45%-8.09%-10.72%-28.13%+46.14%
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
-1.74%-4.13%-7.47%+1,414,999,900.00%+1,414,999,900.00%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-3.02%-7.66%-12.07%-30.20%+315.77%
Enhabit, Inc. stock logo
EHAB
Enhabit
+0.07%+0.36%-1.35%+23.17%+34.59%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arvinas, Inc. stock logo
ARVN
Arvinas
2.40
Hold$14.8654.68% Upside
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
1.00
SellN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
2.80
Moderate Buy$12.78231.46% Upside
Enhabit, Inc. stock logo
EHAB
Enhabit
2.11
Hold$13.57-1.62% Downside

Current Analyst Ratings Breakdown

Latest BRBI, EHAB, CTMX, and ARVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/11/2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Lower Price TargetBuy$17.00 ➝ $11.00
5/4/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Boost Price TargetBuy$21.00 ➝ $24.00
4/27/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
DowngradeHoldStrong Sell
4/14/2026
Enhabit, Inc. stock logo
EHAB
Enhabit
Reiterated RatingSell (D-)
4/10/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Reiterated RatingSell (D-)
3/23/2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Boost Price TargetOverweight$10.00 ➝ $12.00
3/19/2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
DowngradeHold (C-)Sell (D)
3/19/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Boost Price TargetBuy$18.00 ➝ $21.00
3/19/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Boost Price TargetBuy$14.00 ➝ $16.00
3/19/2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Boost Price TargetOverweight$10.00 ➝ $16.00
3/18/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Set Price Target$10.00
(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arvinas, Inc. stock logo
ARVN
Arvinas
$262.60M2.36N/AN/A$6.76 per share1.42
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
N/AN/AN/AN/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$76.20M8.61N/AN/A$0.58 per share6.65
Enhabit, Inc. stock logo
EHAB
Enhabit
$1.06B0.66$1.96 per share7.03$11.05 per share1.25
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arvinas, Inc. stock logo
ARVN
Arvinas
-$80.80M-$1.28N/AN/AN/A-30.77%-14.25%-9.31%5/12/2026 (Estimated)
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
N/AN/AN/AN/AN/AN/AN/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-$17.37M-$0.41N/AN/AN/A-166.40%-54.37%-36.59%N/A
Enhabit, Inc. stock logo
EHAB
Enhabit
-$4.60M-$0.09N/A23.78N/A-0.30%7.24%3.48%N/A

Latest BRBI, EHAB, CTMX, and ARVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
Arvinas, Inc. stock logo
ARVN
Arvinas
-$0.95-$0.90+$0.05-$0.90$16.61 million$15.60 million
5/7/2026Q1 2026
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
N/A$0.09N/A$0.09N/A$25.95 million
5/7/2026Q1 2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-$0.14-$0.10+$0.04-$0.10$4.68 million$10.26 million
3/31/2026Q1 2026
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
N/A$0.09N/A$0.09N/A$25.95 million
3/16/2026Q4 2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-$0.08-$0.22-$0.14-$0.22$7.33 million$0.66 million
3/5/2026Q4 2025
Enhabit, Inc. stock logo
EHAB
Enhabit
$0.14$0.14N/A-$0.76$270.56 million$270.40 million
2/24/2026Q4 2025
Arvinas, Inc. stock logo
ARVN
Arvinas
-$0.55-$1.10-$0.55-$1.10$37.26 million$9.50 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Arvinas, Inc. stock logo
ARVN
Arvinas
N/AN/AN/AN/AN/A
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
$0.745.28%N/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/AN/AN/AN/AN/A
Enhabit, Inc. stock logo
EHAB
Enhabit
N/AN/AN/AN/AN/A

Latest BRBI, EHAB, CTMX, and ARVN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/8/2026
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
quarterly$0.14704.08%5/19/20265/19/20266/5/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arvinas, Inc. stock logo
ARVN
Arvinas
N/A
4.92
4.92
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
N/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/A
3.09
3.09
Enhabit, Inc. stock logo
EHAB
Enhabit
0.70
1.56
1.56

Institutional Ownership

CompanyInstitutional Ownership
Arvinas, Inc. stock logo
ARVN
Arvinas
95.19%
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
N/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
67.77%
Enhabit, Inc. stock logo
EHAB
Enhabit
N/A

Insider Ownership

CompanyInsider Ownership
Arvinas, Inc. stock logo
ARVN
Arvinas
7.30%
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
N/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
6.60%
Enhabit, Inc. stock logo
EHAB
Enhabit
3.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arvinas, Inc. stock logo
ARVN
Arvinas
42064.52 million59.81 millionOptionable
BR Biopharma, Inc. stock logo
BRBI
BR Biopharma
N/A11.81 millionN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
170170.19 million158.96 millionOptionable
Enhabit, Inc. stock logo
EHAB
Enhabit
10,80051.23 million49.48 millionOptionable

Recent News About These Companies

Enhabit, Inc
Enhabit (EHAB) Q1 2025 Earnings Call Transcript
Enhabit (NYSE:EHAB) CAO Sells $19,094.83 in Stock
TD Cowen downgrades Enhabit (EHAB)
Enhabit: Q4 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arvinas stock logo

Arvinas NASDAQ:ARVN

$9.60 -0.06 (-0.57%)
As of 11:23 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

BR Biopharma stock logo

BR Biopharma NASDAQ:BRBI

$14.00 -0.15 (-1.03%)
As of 10:39 AM Eastern
This is a fair market value price provided by Massive. Learn more.

BRBI BR Partners S.A., through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners S.A. is based in S?o Paulo, Brazil.

CytomX Therapeutics stock logo

CytomX Therapeutics NASDAQ:CTMX

$3.86 -0.01 (-0.13%)
As of 11:23 AM Eastern
This is a fair market value price provided by Massive. Learn more.

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Enhabit stock logo

Enhabit NYSE:EHAB

$13.80 +0.02 (+0.11%)
As of 11:22 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was founded in 1998 and is based in Dallas, Texas.